Both in vivo and in vitro studies were conducted with a rat cell line, PC12. PC12 uptake of At211-MABG was high and clonogenic growth was significantly (P<0.0001) suppressed with a single treatment of dose 0.2 kBq/ml. DNA double-strand breaks, cell cycle arrest at G2/M phase and cell death were all observed. In vivo studies biodistribution studies showed good tumor distribution and retention (29 +/- 9 % injected dose per gram of tissue (%ID/g) at 1 hour and 16 +/-6% %ID/g at 24 hours post injection. A single injection of At211-MABG (555 kBq/head) showed significant (P<0.01) tumor size reduction: relative volume at day 7 of 0.54 +/- 0.12 versus 1.86 +/- .60 % for the control group.
Side effects were tolerable. Radioactivity in normal organs (excepting adrenal and stomach) was timely cleared. No significant (P=0.881) weight reduction was observed at day 7.
Although dose-escalation studies remain, our data indicate that At211-MABG is a promising therapeutic agent for PCC.
Presented By: Yasuhiro Ohshima from Quantum Beam Science Research Directorate, National Institute for Quantum and Radiological Science and Technology, Takasaki, Japan
Written By: William Carithers, Lawrence Berkeley National Laboratory
at the 10th International Symposium on Targeted Alpha Therapy (TAT-10) May 31 - June 1, 2017 - Kanazawa, Japan.